Embolization of the middle meningeal artery vs. second surgery-treatment response and volume course of recurrent chronic subdural hematomas.
Chronic subdural hematoma
Embolization
Recurrence
Treatment response
Volume
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
16
01
2023
accepted:
05
05
2023
medline:
6
7
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
Despite multiple studies on the embolization of the middle meningeal artery, there is limited data on the treatment response of recurrent chronic subdural hematomas (CSDH) to embolization and on the volume change. We retrospectively compared the treatment response and volume change of recurrent CSDHs in a conventional group (second surgery) with an embolization group (embolization as stand-alone treatment) during the time-period from August 2019 until June 2022. Different clinical and radiological factors were assessed. Treatment failure was defined as necessity of treatment for second recurrence. Hematoma volumes were determined in the initial CT scan before first surgery, after the first surgery, before retreatment as well as in an early (1 day-2 weeks) and in a late follow-up CT scan (2-8 weeks). Fifty recurrent hematomas after initial surgery were treated either by second surgery (n = 27) or by embolization (n = 23). 8/27 (26,6%) surgically treated and 3/23 (13%) of the hematomas treated by embolization needed to be treated again. This leads to an efficacy in recurrent hematomas of 73,4% in surgically treated and of 87% in embolized hematomas (p = 0.189). In the conventional group, mean volume decreased significantly already in the first follow-up CT scan from 101.7 ml (SD 53.7) to 60.7 ml (SD 40.3) (p = 0.001) and dropped further in the later follow-up scan to 46.6 ml (SD 37.1) (p = 0.001). In the embolization group, the mean volume did decrease insignificantly from 75.1 ml (SD 27.3) to 68 ml (SD 31.4) in the first scan (p = 0.062). However, in the late scan significant volume reduction to 30.8 ml (SD 17.1) could be observed (p = 0.002). Embolization of the middle meningeal artery is an effective treatment option for recurrent CSDH. Patients with mild symptoms who can tolerate slow volume reduction are suitable for embolization, whereas patients with severe symptoms should be reserved for surgery.
Sections du résumé
BACKGROUND
Despite multiple studies on the embolization of the middle meningeal artery, there is limited data on the treatment response of recurrent chronic subdural hematomas (CSDH) to embolization and on the volume change.
METHODS
We retrospectively compared the treatment response and volume change of recurrent CSDHs in a conventional group (second surgery) with an embolization group (embolization as stand-alone treatment) during the time-period from August 2019 until June 2022. Different clinical and radiological factors were assessed. Treatment failure was defined as necessity of treatment for second recurrence. Hematoma volumes were determined in the initial CT scan before first surgery, after the first surgery, before retreatment as well as in an early (1 day-2 weeks) and in a late follow-up CT scan (2-8 weeks).
RESULTS
Fifty recurrent hematomas after initial surgery were treated either by second surgery (n = 27) or by embolization (n = 23). 8/27 (26,6%) surgically treated and 3/23 (13%) of the hematomas treated by embolization needed to be treated again. This leads to an efficacy in recurrent hematomas of 73,4% in surgically treated and of 87% in embolized hematomas (p = 0.189). In the conventional group, mean volume decreased significantly already in the first follow-up CT scan from 101.7 ml (SD 53.7) to 60.7 ml (SD 40.3) (p = 0.001) and dropped further in the later follow-up scan to 46.6 ml (SD 37.1) (p = 0.001). In the embolization group, the mean volume did decrease insignificantly from 75.1 ml (SD 27.3) to 68 ml (SD 31.4) in the first scan (p = 0.062). However, in the late scan significant volume reduction to 30.8 ml (SD 17.1) could be observed (p = 0.002).
CONCLUSIONS
Embolization of the middle meningeal artery is an effective treatment option for recurrent CSDH. Patients with mild symptoms who can tolerate slow volume reduction are suitable for embolization, whereas patients with severe symptoms should be reserved for surgery.
Identifiants
pubmed: 37247035
doi: 10.1007/s00701-023-05621-7
pii: 10.1007/s00701-023-05621-7
pmc: PMC10319706
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1967-1974Informations de copyright
© 2023. The Author(s).
Références
J Neurointerv Surg. 2019 Sep;11(9):912-915
pubmed: 30798265
J Neurointerv Surg. 2022 Sep 22;:
pubmed: 36137743
J Neurosurg. 2019 Mar 22;132(4):1147-1157
pubmed: 30901751
World Neurosurg. 2022 Sep;165:e581-e587
pubmed: 35768059
Neurosurgery. 2022 Sep 1;91(3):389-398
pubmed: 35551167
World Neurosurg. 2017 May;101:520-527
pubmed: 28249828
J Clin Neurosci. 2021 Dec;94:70-75
pubmed: 34863465
J Neuroinflammation. 2017 May 30;14(1):108
pubmed: 28558815
Diagnostics (Basel). 2021 Feb 07;11(2):
pubmed: 33562252
World Neurosurg. 2021 Jul;151:e407-e417
pubmed: 33892165
J Neurointerv Surg. 2020 Dec;12(12):1214-1218
pubmed: 32601261
Medicine (Baltimore). 2017 Jun;96(26):e7290
pubmed: 28658127
World Neurosurg. 2018 Oct;118:e570-e574
pubmed: 30257310
Front Neurosci. 2021 Dec 08;15:786513
pubmed: 34955733
J Neurosurg. 2021 Nov 26;:1-14
pubmed: 34826814
World Neurosurg. 2022 Aug;164:e568-e573
pubmed: 35552029
Neurosurgery. 2021 Jan 13;88(2):268-277
pubmed: 33026434
J Neurointerv Surg. 2021 Oct;13(10):964-967
pubmed: 33883211
J Stroke Cerebrovasc Dis. 2022 Apr;31(4):106318
pubmed: 35121536
J Neurosurg. 2015 Nov;123(5):1209-15
pubmed: 25794342
Neurosurg Focus. 2020 Oct;49(4):E5
pubmed: 33002874
Brain Circ. 2020 Dec 29;6(4):254-259
pubmed: 33506148
J Neurointerv Surg. 2022 Oct;14(10):1027-1032
pubmed: 35135849
J Neurointerv Surg. 2021 Oct;13(10):951-957
pubmed: 34193592
World Neurosurg. 2022 Dec;168:e376-e380
pubmed: 36243361
Neurol Int. 2022 Aug 26;14(3):683-695
pubmed: 36135992
World Neurosurg. 2017 Dec;108:948-953
pubmed: 28935548